Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
about
New advances in targeted gastric cancer treatmentMolecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular CarcinomaMechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapySystemic therapy of hepatocellular carcinoma: current status and future perspectivesImplications of biomarkers in human hepatocellular carcinoma pathogenesis and therapyCurrent systemic treatment of hepatocellular carcinoma: A review of the literatureAngiogenesis Inhibitors for the Treatment of Hepatocellular CarcinomaHepatocellular carcinoma: Where there is unmet needFeasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib.A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapiesOncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implicationsSecond-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategiesPhase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.Akt and mTORC1 have different roles during liver tumorigenesis in mice.Antiangiogenic therapies for advanced hepatocellular carcinoma.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinomaMipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.Clinical trials in hepatocellular carcinoma: an update.The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapyBrivanib: a review of development.Pathways and targets in hepatocellular carcinoma.New agents on the horizon in hepatocellular carcinoma.Targeted therapies in the treatment of advanced hepatocellular carcinomaSystemic therapies in hepatocellular carcinoma: present and future.Molecular targeted therapy for hepatocellular carcinoma: current and future.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Hepatocellular carcinoma review: current treatment, and evidence-based medicine.Advances in managing hepatocellular carcinoma.
P2860
Q26738548-F0D213D4-9D34-48AE-834F-1693DD861F21Q26766689-F9DECB42-25B9-43C0-BC42-9C62D3F60E04Q26797535-3A30CBB5-8214-444D-9B60-CCFBB7F64E11Q26798462-794DE511-734D-48F4-A073-9DA26635EBB4Q26865844-A222A04A-9883-4691-ABAA-D96D2576B1A1Q27005850-B89DABC3-555B-4309-856A-579673A25650Q27026036-2BEACD52-7553-4BB0-9726-FF5AEEE96896Q28075305-BBF5AA08-E2A1-42BF-A49B-B9C7958234F5Q28084046-2E1DD8CB-7047-4E5F-B26B-7FF9118201FCQ33411190-029E4D40-83A9-4442-9EF6-D2A3274E7F18Q33419633-DB576AD0-72D6-4A67-B6CC-5DEFAF5F184EQ33648955-E8242C79-091E-4484-A069-8FE654583EB1Q33895113-A2702DBE-A66B-472E-81C3-576289E20A46Q34438331-68BDB507-E619-42DE-BB2A-15F8BE8D1092Q34781699-44B1845D-B0F4-4A53-824D-2DE686BE745BQ35141906-67EBC470-8291-4841-BA58-9C5E6E7C175AQ35501246-76E12CD4-04CB-4DA8-8A5C-A7A223298B0AQ35739362-03E65AC9-9CE2-4261-AC92-CAA002A387EFQ35759606-8AF3D31F-B0CD-4C86-A36C-0BD21547F48DQ35911679-C09C5EE2-A319-43E2-967A-25097AC67816Q36561567-5084085B-44D5-46EA-9FAB-66823242760AQ36598514-6D56A6A8-2C64-430A-B4B2-68A72CEF29B4Q36788158-6516D28A-335C-4D40-8351-B71E6D368553Q36804518-EBB70877-D7BC-4111-A218-B527F9ABE8C2Q37049104-8B9E8687-AB96-49DC-83CD-F6ADDF2D4AA7Q37175085-C7484C1D-DA9E-4D75-A358-6A3FE3087927Q37274132-94C13B5B-8226-413B-AA8F-38F07651C50CQ37435638-C54B5A0F-ACF3-4CAF-A3A3-FD8F0B4957D0Q37606028-B143518C-CF13-4A3E-B110-D1EF993F01E8Q38048883-BDF90A1D-5993-4012-9889-04E659E5181BQ38062022-916C8A05-6F79-406E-AA48-09EB65C6D07EQ38074429-D474B228-E164-4F1B-A50D-6260A79055BCQ38114062-3E6A0B66-C62E-4D33-B14C-7235D9BD1401Q38150875-050B932A-FEEC-495F-914D-727FC3DF008CQ38151670-A3C50597-4E0D-46DC-9870-654B9B952059Q38160838-91851372-686B-494C-9ED1-B589EFF5B777Q38166329-922C2F69-41DB-4335-8CE3-59D727E1654EQ38184582-9C28E234-0DA1-473D-AD4E-953387E64208Q38207012-AA9AB825-C7E9-4022-8738-BC4C615635FAQ38210345-B4A89BDC-B005-471D-8572-8C0379BEA96B
P2860
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@ast
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@en
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@nl
type
label
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@ast
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@en
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@nl
prefLabel
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@ast
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@en
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@nl
P2093
P1476
Phase II, open-label study of ...... nced hepatocellular carcinoma.
@en
P2093
Blase N Polite
Christine Baudelet
Demetrios Manekas
Ho Yeong Lim
Ian Walters
Joong-Won Park
Mary Mulcahy
Richard S Finn
Yoon-Koo Kang
P304
P356
10.1158/1078-0432.CCR-11-1991
P407
P577
2012-01-11T00:00:00Z